Apogee stock soars after positive atopic dermatitis trial data

Published 07/07/2025, 12:08
© Reuters.

Investing.com -- Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ:APGE) stock surged 24% on Monday after the clinical-stage biotechnology company announced positive 16-week data from its Phase 2 APEX clinical trial of APG777 in moderate-to-severe atopic dermatitis.

The company reported that APG777, its anti-IL-13 antibody, met all primary and key secondary endpoints in the trial. The treatment demonstrated a 71.0% decrease from baseline in the Eczema Area Severity Index (EASI) at Week 16, compared to 33.8% for placebo.

Notably, 66.9% of patients receiving APG777 achieved EASI-75 (a 75% improvement in symptoms), representing a 42.5% placebo-adjusted efficacy rate. According to the company, this is the highest topline and placebo-adjusted efficacy of any biologic in a global study for this condition.

"The Phase 2 Part A results are exciting, with APG777 demonstrating promising efficacy results from only four injection days over the initial 16-week induction period," said Emma Guttman-Yassky, M.D., Ph.D., from the Icahn School of Medicine at Mount Sinai in New York City.

Researchers observed an exposure-response relationship across multiple endpoints, with patients in the highest exposure quartiles achieving EASI-75 response rates of 83.3% and 89.5%. This finding has prompted the company to accelerate its APEX Part B trial, which is testing higher exposures, with results now expected by mid-2026.

APG777 was well tolerated with a favorable safety profile consistent with other agents in its class. Serious treatment-emergent adverse events were rare (1.2% vs. 2.4% in placebo), and the discontinuation rate due to adverse events was low at 2.4%.

The company is also evaluating 3- or 6-month maintenance dosing in APEX Part A, with 52-week data anticipated in the first half of 2026. Additionally, Apogee has begun dosing patients in a Phase 1b head-to-head trial of APG279 (IL-13 + OX40L) versus DUPIXENT, with results expected in the second half of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.